Top

Applied Health Economics and Health Policy

Published in:

Open Access 18-01-2023 | Naloxone | Original Research Article

The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment

Authors: Meghan McGee, Kellia Chiu, Rahim Moineddin, Abhimanyu Sud

Published in: Applied Health Economics and Health Policy | Issue 3/2023

Abstract

Background

Buprenorphine-naloxone is an essential part of the response to opioid poisoning rates in North America. Manipulating market exclusivity is a strategy manufacturers use to increase profitability, as evidenced by Suboxone in the USA.

Objective

To investigate excess costs of buprenorphine-naloxone due to unmerited market exclusivity (no legal patent or data protection) in Canada.

Methods

Using controlled interrupted time-series, this study examined changes in the cost of buprenorphine-naloxone before and after the first generics were listed on public formularies. Methadone cost was the control. Public data from the Canadian Institute of Health Information in British Columbia, Manitoba, and Saskatchewan were used. All buprenorphine-naloxone and methadone claims (2010–2019) accepted for payment by the provincial drug plan/programme were collected. Primary outcome was mean cost per mg of buprenorphine-naloxone after the first listing of generics.

Results

Mean cost per mg of buprenorphine-naloxone before the first listing of generics was $1.21 CAD in British Columbia, $1.27 CAD in Manitoba, and $0.85 CAD in Saskatchewan. Following the introduction of generics, the cost per mg decreased by $0.22 CAD (95% CI − 0.33 to − 0.10; p = 0.0014) in British Columbia, $0.36 CAD (95% CI − 0.58 to − 0.13; p = 0.004) in Manitoba, and $0.27 CAD (95% CI − 0.50 to − 0.05; p = 0.03) in Saskatchewan. Mean cost per mg decreased by $0.26 CAD (95% CI − 0.38 to − 0.13; p = 0.0004) after a third generic was introduced in British Columbia. Excess costs to public formularies during the 4- to 5-year period prior to the listing of generics were $1,992,558 CAD in British Columbia, $80,876 CAD in Manitoba, and $4130 CAD in Saskatchewan. If buprenorphine-naloxone cost $0.61 CAD (mean cost after the third generic entered) instead of $1.21 CAD per mg during the pre-generics period, public payers in British Columbia could have saved $5,016,220 CAD between 2011 and 2015.

Conclusions

Unmerited 6 years of market exclusivity for brand-name buprenorphine-naloxone in Canada resulted in substantial excess costs. There is an urgent need to implement policies that can help reduce costs for high-priority drugs in Canada.

Available only for authorised users

Centre for Addiction and Mental Health. Opioid agonist therapy: a synthesis of Canadian guidelines for treating opioid use disorder. 2021.

Health and Human Services Department. Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Fed Reg. 2021;86:22439–40.

Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:1550. https://doi.org/10.1136/bmj.j1550.CrossRef

Health Canada. Surveillance of opioid- and stimulant-related harms in Canada. 2021.

Ahamad K, Kerr T, Nolan S, Wood E. Moving towards improved access for evidence-based opioid addiction care in British Columbia. 2016.

Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Barriers and facilitators to the use of medications for opioid use disorder: a rapid review. J Gen Intern Med. 2020;35:954–63. https://doi.org/10.1007/s11606-020-06257-4.CrossRefPubMedPubMedCentral

Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: Issues, regulation and evidence. Econ Policy. 2008;23:500–44. https://doi.org/10.1111/j.1468-0327.2008.00207.x.CrossRef

Lexchin J. Market exclusivity time for top selling originator drugs in Canada: a cohort study. Value Health. 2017;20:1139–42. https://doi.org/10.1016/j.jval.2017.05.004.CrossRefPubMed

Sud A, McGee M, Mintzes B, Herder M. Permissive regulation: a critical review of the regulatory history of buprenorphine formulations in Canada. Int J Drug Policy. 2022;105:103749. https://doi.org/10.1016/j.drugpo.2022.103749.CrossRefPubMed

10.

Zhang W, Sun H, Guh DP, Lynd LD, Hollis A, Grootendorst P, et al. The impact of tiered-pricing framework on generic entry in Canada. Int J Health Policy Manag. 2020. https://doi.org/10.34172/ijhpm.2020.215.CrossRefPubMedCentral

11.

Hollis A. Generic drugs in Canada: an examination of tiered pricing. CMAJ. 2015;187:1033–4. https://doi.org/10.1503/cmaj.150395.CrossRefPubMedPubMedCentral

12.

Gupta R, Morten CJ, Zhu AY, Ramachandran R, Shah ND, Ross JS. Approvals and timing of new formulations of novel drugs approved by the US food and drug administration between 1995 and 2010 and followed through 2021. JAMA Health Forum. 2022;3:e221096–e221096. https://doi.org/10.1001/jamahealthforum.2022.1096.CrossRefPubMedPubMedCentral

13.

The United States Department of Justice. Justice Department Obtains $1.4 Billion from Reckitt Benckiser Group in Largest Recovery in a Case Concerning an Opioid Drug in United States History 2019. https://www.justice.gov/opa/pr/justice-department-obtains-14-billion-reckitt-benckiser-group-largest-recovery-case (accessed March 22, 2022).

14.

Haffajee RL, Frank RG. Generic drug policy and suboxone to treat opioid use disorder. J Law Med Ethics. 2019;47:43–53. https://doi.org/10.1177/1073110519898042.CrossRefPubMed

15.

Clemans-Cope L, Epstein M, Kenney GM. Rapid Growth in Medicaid Spending on Medications to Treat Opioid Use Disorder and Overdose 2017. https://www.urban.org/sites/default/files/publication/91521/2001386-rapid-growth-in-medicaid-spending-on-medications-to-treat-opioid-use-disorder-and-overdose_3.pdf (accessed June 21, 2022).

16.

Grootendorst P. Brand drug companies impeding generic drug company access to product samples: estimated prevalence and impact on drug costs. J Gen Med. 2022;18:10–20. https://doi.org/10.1177/17411343211035168.CrossRef

17.

Roberts EA, Herder M, Hollis A. Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy. CMAJ. 2015;187:422–5. https://doi.org/10.1503/cmaj.140308.CrossRefPubMedPubMedCentral

18.

Ordean A, Wong S, Graves L. No. 349-substance use in pregnancy. J Obstet Gynaecol Can. 2017;39:922–37. https://doi.org/10.1016/j.jogc.2017.04.028.CrossRefPubMed

19.

Health Canada. Drug Product Database: Access the database. Drug Product Database: Access the Database 2015. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (accessed March 22, 2022).

20.

Health Canada. Notice of Compliance search 2010. https://health-products.canada.ca/noc-ac/newSearch-nouvelleRecherche.do (accessed June 20, 2022).

21.

Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations n.d. https://www.equator-network.org/reporting-guidelines/cheers/ (accessed June 30, 2022).

22.

Canadian Institute for Health Information. National Prescription Drug Utilization Information System metadata n.d.

23.

Government of Canada, Statistics Canada. Population estimates, quarterly 2022.

24.

Chapman SR, Aladul MI, Fitzpatrick RW. Lost cost savings to the NHS in England due to the delayed entry of multiple generic low-dose transdermal buprenorphine: a case scenario analysis. BMJ Open. 2019;9:26817. https://doi.org/10.1136/bmjopen-2018-026817.CrossRef

25.

Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy. 2004;68:47–54. https://doi.org/10.1016/j.healthpol.2003.07.007.CrossRefPubMed

26.

Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27:299–309. https://doi.org/10.1046/j.1365-2710.2002.00430.x.CrossRefPubMed

27.

Linden A, Adams JL. Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation. J Eval Clin Pract. 2011;17:1231–8. https://doi.org/10.1111/j.1365-2753.2010.01504.x.CrossRefPubMed

28.

The CIHR Canadian Research Initiative in Substance Misuse. CRISM national guideline for the clinical management of opioid use disorder. 2018.

29.

Roberts AW, Saloner B, Dusetzina SB. Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015. Psychiatr Serv. 2018;69:832–5. https://doi.org/10.1176/appi.ps.201700315.CrossRefPubMedPubMedCentral

30.

Barenie RE, Sinha MS, Kesselheim AS. Factors affecting buprenorphine utilization and spending in Medicaid, 2002–2018. Value Health. 2021;24:182–7. https://doi.org/10.1016/j.jval.2020.04.1840.CrossRefPubMed

31.

Wouters OJ, Kanavos PG, McKEE M. Comparing generic drug markets in Europe and the United States: prices, volumes, and spending. Milbank Q. 2017;95:554–601. https://doi.org/10.1111/1468-0009.12279.CrossRefPubMedPubMedCentral

32.

Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strategy. 1997;6:75–90. https://doi.org/10.1111/j.1430-9134.1997.00075.x.CrossRef

33.

Government of British Columbia. Low Cost Alternative (LCA) Program 2021. https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/pharmacare/prescribers/how-pharmacare-covers-drugs-in-the-low-cost-alternative-lca-program (accessed June 2, 2022).

34.

Howard JN, Harris I, Frank G, Kiptanui Z, Qian J, Hansen R. Influencers of generic drug utilization: a systematic review. Res Social Adm Pharm. 2018;14:619–27. https://doi.org/10.1016/j.sapharm.2017.08.001.CrossRefPubMed

35.

Sud A, Strang M, Buchman DZ, Spithoff S, Upshur REG, Webster F, et al. How the suboxone education programme presented as a solution to risks in the Canadian opioid crisis: a critical discourse analysis. BMJ Open. 2022;12:59561. https://doi.org/10.1136/bmjopen-2021-059561.CrossRef

36.

Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X Waiver. JAMA Psychiat. 2019;76:229–30. https://doi.org/10.1001/jamapsychiatry.2018.3685.CrossRef

Title: The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment
Authors: Meghan McGee
Kellia Chiu
Rahim Moineddin
Abhimanyu Sud
Publication date: 18-01-2023
Publisher: Springer International Publishing
Keywords: Naloxone
Buprenorphine
Opioids
Opioids
Published in: Applied Health Economics and Health Policy / Issue 3/2023
Print ISSN: 1175-5652
Electronic ISSN: 1179-1896
DOI: https://doi.org/10.1007/s40258-022-00787-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Impact of Suboxone’s Market Exclusivity on Cost of Opioid Use Disorder Treatment

Abstract

Background

Objective

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2023

Stakeholder Engagement in the Development of Public Health Economic Models: An Application to Modelling of Minimum Unit Pricing of Alcohol in South Africa

Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?

Measurement of Health-Related Quality of Life from Conception to Postpartum Using the EQ-5D-5L Among a National Sample of US Pregnant and Postpartum Adults

Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends

Medication Adherence and Healthcare Costs in Chronically Ill Patients Using German Claims Data

The Broader Opportunity Costs in the Broader Cost-Effectiveness Analysis Framework